Updated Japanese multicenter registry study evaluates the efficacy and safety of proton beam therapy for treating extrahepatic cholangiocarcinoma.

ABSTRACT: This study aimed to analyze the efficacy and safety of a prospective, multicenter registry study of proton beam therapy (PBT) for extrahepatic cholangiocarcinoma (EHC) in Japan. Patients who underwent PBT for EHC between May 2016 and June 2021 were registered in the Particle Beam Therapy Committee and Subcommittee of the Japanese Society for Radiation Oncology. We updated the overall survival (OS), progression-free survival (PFS), local control rate (LC), and toxicity. Among 201 registered cases, 124 cases including elder population (median age 76 years old, range; 44-91) with initial definitive PBT were evaluated. The follow-up period for survivors was 18.3 months, the median OS time was 20.0 months (95% CI: 17.3-22.8 months), and the 2-year OS rate was 36.9% (27.3-46.4%). The 2-year LC a

SUBMITTER: Yamazaki H 

PROVIDER: S-EPMC12222466 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature